Cancer

Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia

Retrieved on: 
Monday, May 16, 2022 - 8:11am

Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.

Key Points: 
  • Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.
  • Naveed Siddiqi, Senior Partner at Novo Holdings, serves as a Board Member of F2G and Eric Snyder, Partner at Novo Holdings, as Board Observer.
  • Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections.
  • Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.

Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia

Retrieved on: 
Monday, May 16, 2022 - 8:09am

Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.

Key Points: 
  • Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.
  • Naveed Siddiqi, Senior Partner at Novo Holdings, serves as a Board Member of F2G and Eric Snyder, Partner at Novo Holdings, as Board Observer.
  • Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections.
  • Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.

Tethis launches See.d®, the first fully automated, standardized pre-analytical platform for comprehensive liquid biopsy testing

Retrieved on: 
Monday, May 16, 2022 - 8:00am

MILAN, May 16, 2022 /PRNewswire/ -- Tethis S.p.A announces the release of See.d®, the first universal blood sample preparator for liquid biopsy analysis. This innovative technology performs a completely automated and standardized preparation of a blood sample at the point of blood collection. Cellular fraction is gently stabilized on proprietary, nanocoated SBS slides for rare cell detection, including CTCs, while plasma is made available for the analysis of cell-free content.

Key Points: 
  • This innovative technology performs a completely automated and standardized preparation of a blood sample at the point of blood collection.
  • See.d processes fresh blood collected in EDTA tubes shortly after collection (within 4 to 6 hours) favoring maximum sample integrity.
  • "This is a key development milestone not just for Tethis but hopefully for liquid biopsy adoption" said Mr. Gian Martino Franchi, Chief Technology Officer of the company.
  • "It's a first step towards true multi-analytical, standardized liquid biopsy tests involving all possible tumor content released in the bloodstream.

Tethis launches See.d®, the first fully automated, standardized pre-analytical platform for comprehensive liquid biopsy testing

Retrieved on: 
Monday, May 16, 2022 - 8:00am

MILAN, May 16, 2022 /PRNewswire/ -- Tethis S.p.A announces the release of See.d®, the first universal blood sample preparator for liquid biopsy analysis. This innovative technology performs a completely automated and standardized preparation of a blood sample at the point of blood collection. Cellular fraction is gently stabilized on proprietary, nanocoated SBS slides for rare cell detection, including CTCs, while plasma is made available for the analysis of cell-free content.

Key Points: 
  • This innovative technology performs a completely automated and standardized preparation of a blood sample at the point of blood collection.
  • See.d processes fresh blood collected in EDTA tubes shortly after collection (within 4 to 6 hours) favoring maximum sample integrity.
  • "This is a key development milestone not just for Tethis but hopefully for liquid biopsy adoption" said Mr. Gian Martino Franchi, Chief Technology Officer of the company.
  • "It's a first step towards true multi-analytical, standardized liquid biopsy tests involving all possible tumor content released in the bloodstream.

Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies

Retrieved on: 
Monday, May 16, 2022 - 7:25am

TURKU, Finland and BOSTON, May 16, 2022 /PRNewswire/ -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that both the U.S. Food and Drug Administration (FDA) and Finnish Medicines Agency (FIMEA) have cleared Faron's Investigational New Drug (IND) application to begin the Company sponsored BEXMAB study. BEXMAB is a novel Phase I/II study to assess safety, tolerability and preliminary efficacy of bexmarilimab, Faron's wholly-owned investigational precision cancer immunotherapy, in combination with standard of care (SoC) therapy in patients with relapsed acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CML). This marks the first time bexmarilimab will be assessed as part of a clinical study in hematologic malignancies.

Key Points: 
  • In mouse models, bexmarilimab has successfully blocked or silenced Clever-1, activating antigen presentation and promoting interferon gamma secretion by leukocytes.
  • As an immuno-oncology therapy, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules.
  • Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system.
  • Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Monday, May 16, 2022 - 1:00am

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic, ophthalmologyand other major diseases.

Key Points: 
  • Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic, ophthalmologyand other major diseases.
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
  • Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

Inmagene Receives FDA IND Clearance for a Third Generation BTK Inhibitor Targeting Immunological Diseases

Retrieved on: 
Monday, May 16, 2022 - 12:00am

Inmagene is developing the drug candidate to potentially treat immunological diseases.

Key Points: 
  • Inmagene is developing the drug candidate to potentially treat immunological diseases.
  • "This is the third IND clearance Inmagene has obtained since the beginning of 2022," said Dr. Jonathan Wang, Chairman and CEO of Inmagene.
  • IMG-004's improved activity, selectivity, and pharmacokinetic profile in preclinical studies compared to those of other BTK inhibitors point toward a best-in-class potential.
  • IMG-004 is a non-covalent, reversible small molecule inhibitor targeting Bruton's tyrosine kinase (BTK).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lucid, AbbVie, Playstudios, and Twitter and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, May 14, 2022 - 2:00am

On this news, Lucids common stock fell $3.99, or 13.8%, to close at $24.99 per share on March 1, 2022, thereby injuring investors.

Key Points: 
  • On this news, Lucids common stock fell $3.99, or 13.8%, to close at $24.99 per share on March 1, 2022, thereby injuring investors.
  • For more information on the Lucid class action go to: https://bespc.com/cases/LCID
    AbbVie is one of the world's largest pharmaceutical companies.
  • For more information on the Twitter class action go to: https://bespc.com/cases/TWTR
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lucid, AbbVie, Playstudios, and Twitter and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, May 14, 2022 - 2:00am

On this news, Lucids common stock fell $3.99, or 13.8%, to close at $24.99 per share on March 1, 2022, thereby injuring investors.

Key Points: 
  • On this news, Lucids common stock fell $3.99, or 13.8%, to close at $24.99 per share on March 1, 2022, thereby injuring investors.
  • For more information on the Lucid class action go to: https://bespc.com/cases/LCID
    AbbVie is one of the world's largest pharmaceutical companies.
  • For more information on the Twitter class action go to: https://bespc.com/cases/TWTR
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer

Retrieved on: 
Friday, May 13, 2022 - 9:21pm

We are excited about the collaboration with AstraZeneca to investigate the combination of SI-B001 and a leading third-generation EGFR TKI for patients with NSCLC.

Key Points: 
  • We are excited about the collaboration with AstraZeneca to investigate the combination of SI-B001 and a leading third-generation EGFR TKI for patients with NSCLC.
  • SI-B001 can also induce endocytosis of EGFR and HER3, and down-regulate the levels of EGFR and HER3 tumor cells.
  • Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% classified as NSCLC.
  • With multiple in-house proprietary platforms for innovative biopharmaceuticals, Baili has built a robust pipeline to benefit cancer patients around the world.